---

1. Indian frankincense is

A. Ferula gummosa B. Boswellia serrate C. Commiphora myrrha D. Boswellia sacra

---

2. Luminescence, fluorescence and phosphorescence are the types of _________

A. Transmittance B. Absorption spectroscopy C. Both (a) and (b) D. Emission spectroscopy

---

3. Which of the following genera consists of endospore forming bacteria

A. Streptococcus B. Bacillus C. Escherichia D. Saccharomyces

---

4. A simple interest on a certain sum for 3 years is Rs. 225 and the compound interest on the same sum for 2 years is Rs. 165. Find the rate percent per annum

A. 20% B. 15% C. 2.5% D. 5%

---

5. Polypharmacy means________

A. Science polymorphism B. Use of multiple medication by a patient C. Use of combination of drugs D. Medication in geriatric patient

---

6. What is the mechanism of Saroglitazar, a novel first in class drug?

A. GLP-1 receptor agonists B. DPP IV inhibitor C. dual PPAR agonist D. Aldose reductase inhibitors

---

7. Identify the soft acids

A. Cu+, Ag+, Hg+, CO+ B. RPO2+, ROPO2+, RSO2+, ROSO2+ C. Na+, K+, Li+,Mg2+ D. Ca2+, Mn2+, Sr2+, Al3+

---

8. C-peptide assay in hyperglycemic patient is done to determine……..

A. To check safety of insulin therapy B. To determine type of diabetes C. Elevated blood sugar level D. None of the above

---

9. Which one of the following is a Histamine H1-receptor antagonist

A. 4-(5H-dibenzoja,d] cycloheptane-5-ylidene)-1-methyl piperidine hydrochloride B. 4-(5H-dibenzola,d] cyclohepten-5-ylidene)-1-methyl pyrimidine hydrochloride C. 4-(5H-dibenzo[a,d] cyclohepten-5-ylidene)-1-methyl piperidine hydrochloride D. 4-(5H-dibenzola,d] cyclohepten-5-ylidene)-1-methyl pyridine hydrochloride

---

10. In ANDA, the generic drug product is compared with innovator drug to observe:

A. Patent protection B. Price competition C. Efficacy D. Bioequivalence

---

11. If the aim of these investigations is to determine the stability of a drug after opening of the package what are the conditions

A. Room temp, 0-3 month B. 40°C, 75 RH 0-6 months C. Room temp, 0-4 weeks D. Room temp, 0-24 hours

---

12. _______is the indication of flow property

A. Angel of repose B. Rat holing C. All of the above D. Bridging

---

13. Totipotency is__________

A. All of the above B. Ability of a single cell to differentiate into any of the 3 germ layers: endoderm, mesoderm, ectoderm C. Potential to give rise to cell from multiple, but a limited number of lineages D. Ability of a single cell to divide and produce all the differentiated cells in an organism

---

14. The size of droplet in emulsion is ____________

A. 1-100µm B. 0.1-1µm C. 0.5-50µm D. 5-50µm

---

15. In genetic code, codon degeneracy occurs at ___ position of codon.

A. First B. Third C. Second D. First or third

---

16. The presence of alkaloid in plant material can be tested by the following reagents

A. Aluminum trichloride in alcohol B. 2,4-dinitrophenylhydrazine solution C. 3-dinitrobenzoic acid in NaOH D. Potassium-mercury iodide solution

---

17. Therapeutical index denotes_______

A. Margin of therapy B. Margin of efficacy C. Margin of safety D. All

---

18. Which of the following acids has the highest degree of ionization in an aqueous solution

A. Indomethacin B. Warfarin C. Ibuprofen D. Aspirin

---

19. In which phase micro dosing is directly given to patient without pre-clinical testing?

A. II phase B. 0 phase C. III phase D. I phase

---

20. Karl Fischer titration

A. reduction of I2 by SO2 in presence of water and removal of pyridine sulfate trioxide B. reduction of I2 by SO2 in presence water and by removal of pyridine iodide C. reduction of I2 by SO2 in presence of water and removal of pyridine iodate D. reduction of I2 by pyridine in presence of water, SO2 and removal of pyridine sulfate trioxide